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Abstract
Background: There is a relationship between Chronic Obstructive Pulmonary Disease (COPD) and the development
of lung cancer (LC). The aim of this study is to analyse several blood markers and compare their concentrations in
patients with only COPD and LC + COPD.
Methods: Case-control study with cases presenting combined LC and COPD and two control groups (patients presenting
only COPD and patients presenting only LC). We also included LC patients with descriptive purposes. In both groups,
peripheral blood analyses of TNF-α, IL-6, IL-8, total leukocyte, lymphocyte and neutrophil counts, neutrophil-to-lymphocyte
ratio, total platelet count, mean platelet volume, platelet-to-lymphocyte ratio, alpha 1-antitripsin (A1AT), IgE, C-reactive
protein, fibrinogen, cholesterol and bilirubin were performed. We developed univariate and multivariate analyses of these
markers, as well as a risk score variable, and we evaluated its performance through ROC curves.
Results:We included 280 patients, 109 cases (LC + COPD), 83 controls (COPD) and 88 LC without COPD. No differences
were observed in the distribution by sex, age, BMI, smoking, occupational exposure, lung function, GOLD stage or
comorbidity. Patients with LC + COPD had significantly higher levels of neutrophils [OR 1.00 (95%CI 1.00–1.00), p = 0.03]
and A1AT [OR 1.02 (95%CI 1.01–1.03), p = 0.003] and lower cholesterol levels [OR 0.98 (95%CI 0.97–0.99), p = 0.009] than
COPD controls. We developed a risk score variable combining neutrophils, A1AT and cholesterol, achieving a sensitivity
of 80%, a negative predictive value of 90.7% and an area under the curve of 0.78 (95%CI 0.71–0.86).
Conclusions: COPD patients who also have LC have higher levels of neutrophils and A1AT and lower of cholesterol.
These parameters could be potentially predicting biomarkers of LC in COPD patients.
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Background
Lung cancer (LC) is the leading cause of cancer death
worldwide, with a 5-year survival of approximately 15%.
Chronic Obstructive Pulmonary Disease (COPD) is the
fourth cause of death worldwide, with a current preva-
lence around 10% [1–3]. LC mortality is explained by
the fact that most diagnoses are made in advanced
stages, being able to identify tumors in localized stages
only in 16–22% of cases, although new diagnostic
techniques and the implementation of rapid diagnostic
units are increasing the proportion of patients diagnosed
with localized LC [2, 4]. In these cases, survival can
reach up to 55.6% at 5 years [5].
Some studies have demonstrated that COPD is a risk
factor for LC development, independently of tobacco ex-
posure. In addition, COPD and LC share some common
features. Smoking is the main cause of both diseases,
COPD affecting 15–20% of smokers, while 80% of LC pa-
tients are smokers or ex-smokers. Besides tobacco use,
COPD and LC share some genetic backgrounds, environ-
mental exposures, and common underlying inflammatory
processes [6, 7].
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Airway chronic inflammation is one of the pathophysio-
logical mechanisms that plays a key role in the amplification
of the initial mutagenic response of LC. It is possible that per-
sistent airway inflammation in COPD patients induces alter-
ations in the bronchial epithelium which favor carcinogenesis
[8]. In patients with COPD and in smokers, the expression of
certain cytokines is increased, such as IL-6 and IL-8, which,
in turn, through the induction of the enzyme cyclooxygenase-
2, promote an inflammatory response in lymphocytes. They
can also inhibit apoptosis, interfere with cellular repair mech-
anisms and promote angiogenesis, contributing to neoproli-
ferative processes [8]. Other cytokines and growth factors
such as tumor necrosis factor (TNF)-α have also been shown
to participate in the development, tumor growth and metasta-
sis of LC in patients with underlying respiratory conditions
[9]. In fact, various blood markers of inflammation have been
evaluated separately in patients either with COPD or with LC
and other malignant tumors (Additional file 1: Table S1).
These markers include C-reactive protein (CRP), platelet,
neutrophil, and lymphocyte numbers but especially include
neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio
(PLR), mean platelet volume (MPV), alpha-1-antitripsin
(A1AT), fibrinogen, cholesterol or bilirubin [10–14]. There-
fore, the increased risk of developing LC in patients with
COPD could be related to the existence of a previous inflam-
mation, making them more susceptible to the carcinogenic
components of tobacco. This inflammation persists even
years after having stopped smoking, which may be a cause of
LC in ex-smokers [8]. To our knowledge, there are no studies
assessing a complete series of inflammatory blood markers in
patients with COPD comparing them with LC+COPD pa-
tients. To have some predictive markers in COPD patients
showing a higher possibility of LC would mean an early diag-
nosis and therefore improving their clinical results. We have
selected 16 biomarkers in order to test the importance of per-
sistent airway inflammation in the development of LC in
COPD patients, as these markers have already shown to be
high in COPD and related to disease progression, prognosis
and response to treatment in LC.
The aim of this study is: 1) to assess a panel of different
markers (IL-6, IL-8, TNF-α, CRP, PCR, IgE, platelet, neutro-
phil, and lymphocyte numbers, NLR, PLR, MPV, A1AT,
fibrinogen, cholesterol and bilirubin) in three groups of pa-
tients (COPD, patients with COPD and LC [LC+COPD]
and LC without COPD), focusing on the comparison be-
tween COPD and LC+COPD patients and, 2) to select
those markers associated with LC+COPD and to create a
score to predict the risk of presenting LC based on selected
clinical parameters.
Methods
Study design and case and control selection
This is a case-control study in which patients with
COPD, with LC + COPD and with LC only were
included from September 2014 to May 2018 from the
Vigo University Hospital. This hospital attends a 450,
000-inhabitant area, and the pulmonary department
applies practically all pulmonary techniques and proce-
dures. Cases were COPD patients with synchronic LC
(LC + COPD) diagnosed in the Lung Cancer Rapid
Diagnosis Unit (LCRDU), while controls (patients with
COPD and no evidence of LC) were captured in a gen-
eral pulmonary consultation that was carried out on the
same days as the LCRDU, including patients with re-
cently-diagnosed COPD (less than 6months). We in-
cluded a second group of controls with LC with normal
lung function to make a descriptive comparison of in-
flammatory marker’s levels between the three groups.
The LCRDU permits a diagnostic and staging process of
LC and other thoracic neoplasms. This unit assesses
around 95% of all LC patients in our area.
Patients with symptoms or evidence by imaging tests
of active infection, ischemic or congestive heart disease,
thromboembolic disease or other underlying inflamma-
tory processes (outbreak of connective tissue disease, in-
flammatory bowel disease...), as well as patients with a
second synchronous tumor were excluded from the
study to avoid false positives when assessing blood
markers. In addition, we also excluded all patients with
advanced or very symptomatic tumor disease requiring
hospital admission (hepatic failure, moderate or massive
hemoptysis, superior vena cava syndrome or metastatic
disease requiring urgent treatment, such as palliative
radiotherapy for bone or brain metastases). Therefore,
all patients included in the study were managed on an
outpatient basis in the LCRDU. Also, we excluded pa-
tients presenting with a microbiological isolation in any
of the samples carried out during the process (sputum
cultures or cultures of bronchoscopy or surgery sam-
ples). However, no cut-off points were established as ex-
clusion criteria in the levels of the biomarkers studied,
in order to avoid intervening in the results of the study.
The diagnosis of LC was made after suggestive radio-
logical findings with pathologic confirmation [15].
COPD was defined following the Global Initiative for
Obstructive Lung Disease (GOLD) recommendations as
the presence of persistent respiratory symptoms and a
forced expiratory volume in the first second (FEV1)/
forced vital capacity (FVC) ratio < 0.70 after a broncho-
dilator test [16]. We excluded patients unwilling to par-
ticipate or to donate blood samples, those with
contraindications or incapable of performing spirometric
tests correctly, and patients with any other pulmonary
obstructive disease other than COPD.
We assessed a panel of different blood markers in the
three groups of patients: IL-6, IL-8, TNF-α, CRP, IgE,
platelet, neutrophil, and lymphocyte numbers, NLR,
PLR, MPV, A1AT, fibrinogen, cholesterol and bilirubin,
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and whether patients were receiving growth factors or
statins. All biomarkers were tested in a stable phase, in
outpatients, without any concomitant infection or in-
flammatory process, and without any synchronous
tumor.
Information retrieval
Collected data included basic demographics: age, gender,
tobacco history, functional variables (comorbidity
assessed by the Charlson Comorbidity Index [17], FEV1,
DLCO and body mass index (BMI). The histological type
of LC was also included by reviewing the pathology re-
port, as well as the stage at diagnosis according to the
TNM eight edition’s descriptors [15] after complete sta-
ging processes. Other data necessary for COPD
characterization were included, such as the GOLD and
Spanish Guideline for COPD (GesEPOC) classifications
valid at the study onset [16, 18], COPD assessment test
(CAT) [19] and BODEx index [20].
Smokers were defined as participants who had smoked
100 or more cigarettes in their lifetime. Current smokers
were those who smoked more than one cigarette in the
month prior to enrollment or quit within one year of en-
rollment. The remaining smokers were classified as ex-
smokers. Never smokers were defined as having smoked
less than 100 cigarettes in their lifetime [21].
Spirometry was performed at the time of inclusion in
the study by a technician specialized in respiratory func-
tional tests. It was carried out with a Masterlab pneu-
matic-type spirometer (Jaeger AG, Wuezburg,
Germany), using acceptability and reproducibility criteria
from SEPAR and ERS [22] guidelines, with Quanjer Gli
reference values ( [23]). A bronchodilator test was per-
formed in all cases, by administrating 400 μg of salbuta-
mol in 4 puffs (100 μg per puff) at 30 s intervals.
Emphysema was determined through computed tom-
ography (CT) assessment by experimented radiologists.
The CT studies were performed in two devices: Light-
speed VCT of 64 rows of detectors (GE Medical Sys-
tems, Milwaukee, Wisconsin) and Somatom Emotion of
16 rows of detectors (Siemens Medical Solutions, Enlar-
gen, Germany).
Peripheral venous blood was collected from all pa-
tients into Vacutainer tubes in the morning. Serum was
obtained by centrifugation of whole blood at 3000 g for
10 min. Plasma (CITRATE as anticoagulant) was ob-
tained by centrifugation at 3500 g for 15 min at a
temperature of 4 °C. Serum samples used to measure IL-
6, IL-8 and TNF-α levels were stored at − 80 °C until
they were analyzed. IL-6, IL-8 and TNF-α serum con-
centrations were determined by validated immunoassays
(IMMULITE ONE, Siemens, Germany), full blood
counts were carried out using ADVIA 2120 (Siemens,
Germany); serum CRP, cholesterol and bilirubin were
measured using ADVIA 2400 (Siemens, Germany);
A1AT was analyzed by nephelometric assay (IMMAGE,
Beckman Coulter, USA); IgE levels were measured by
fluorometric immunoassay (PHADIA 250, Thermo Sci-
entific, USA) and fibrinogen was calculated in ACL TOP
700 instrument (Werfen Company, Spain) Limits of de-
tection (LOD) for IL-6, IL-8 and TNF-α were 2 pg/ml, 5
pg/ml and 4 pg/ml. Biomarker concentrations were
below the LOD in some individuals. To avoid a down-
ward bias of the population data, a nominal level of half
of the LOD value was used in the analysis in individuals
with values below the LOD [24].
Statistical analysis
The design and statistics of the study were reviewed by a
professor of epidemiology who is a co-author of the
manuscript, and who has an extensive experience in
case-control studies. We first carried out a descriptive
analysis of levels of all markers in the three groups of
patients through the use of boxplots. Then we developed
a univariate analysis to evaluate differences between
cases (patients with LC + COPD) and controls (COPD)
for all assessed variables. The t-student test was used for
quantitative variables and Chi2 test was used to compare
percentages for qualitative variables. Our limit of signifi-
cance was p < 0.05. We included variables with a p < 0.10
in the multivariate models (performed through a forward
conditional method), developing interaction analyses for
all of them. For the final significant variables, we per-
formed two multivariate logistic regression models, the
first adjusting for age and sex and the second also in-
cluding the remaining variables. To do so, the significant
quantitative variables were stratified into terciles for in-
clusion in the logistic regression models. Application of
this multivariate analyses led to the design of a risk score
variable for each given patient based on the results of
the multivariate logistic regression. Points for a given pa-
tient were obtained by summing all the points for each
predictor variable, adjusted for sex and age. Then we de-
veloped a ROC curve and assessed sensitivity, specificity
and predictive values for the risk score variable, taking
into account a prevalence of LC in patients with COPD
of 25% [7]. The analysis was performed with SPSS 21.0
(IBM Corporation, Armonk, New York).
Results
We included 280 patients: 109 cases (LC + COPD), 83
controls (COPD) and 88 LC patients. A descriptive and
univariate analysis comparing baseline characteristics
and marker levels of cases and controls is included in
Table 1. As shown in the table, baseline characteristics
of both groups were very homogeneous, with no relevant
differences between groups, also in terms of baseline
treatments. There were no patients undertaking any
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growth factor. One case and two controls had A1AT <
90mg/dl. Five patients had cachexia, four were cases
(one in the group with high cholesterol levels and three
with medium cholesterol levels) and one was a control.
Baseline characteristics of LC patients without COPD
are included in Table 2.
The most frequent histological type was adenocar-
cinoma, in 84 cases (44.9%), followed by squamous
(26.7%), undifferentiated (18.2%), small-cell LC
(SCLC) (7%) and carcinoid (3.2%). Regarding tumour
characteristics, when comparing LC + COPD with LC
patients, we found that patients with LC without
COPD had more adenocarcinomas (54.5% vs 38.4%;
p = 0.02), whereas patients with LC + COPD had more
SCLC (17.8% vs 4.9%; p = 0.006). There were no
differences in stage at diagnosis. Figure 1 shows
Table 1 Univariate analysis comparing characteristics of cases and controls
Cases (LC + COPD) Controls (COPD) p
Baseline characteristics
Gender (male), n (%) 95 (87.1) 65 (78.3) 0.07
Age, mean (SD) 67 (10.3) 64.6 (9.4) 0.10
BMI, mean (SD) 26.6 (4.2) 27.3 (4.5) 0.29
Laboral exposure, n (%) 43 (39.4) 25 (30.1) 0.31
Tobacco history, n (%) 109 (100) 82 (98.8) 0.43
Active smokers, n (%) 62 (56.9) 45 (54.2) 0.39
Pack-years, mean (SD) 49.5 (23.8) 47.5 (25) 0.61
Emphysema, n (%) 68 (62.4) 38 (45.8) 0.32
GOLD I-II, n (%) 87 (79.8) 66 (79.5) 0.55
GesEPOC A (%) 105 (96.3) 80 (96.4) 0.65
Bodex, mean (SD) 1 (1.5) 0.8 (1.2) 0.30
CAT, mean (SD) 10.6 (6.2) 9.7 (7.6) 0.69
FEV1 (%), mean (SD) 69.1 (21.1) 71 (20.2) 0.55
DLCO (%), mean (SD) 68.1 (21) 70.4 (22.6) 0.58
Charlson index, mean (SD) 1.0 (1.5) 0.7 (1) 0.11
Statin consumption, n (%) 40 (36.7) 31 (37.3) 0.52
Inflammatory markers
TNF-α (pg/ml), mean (SD) 14.7 (46.4) 9.3 (7.4) 0.25
IL-6 (pg/ml), mean (SD) 10.7 (16.6) 6.2 (12.1) 0.05
IL-8 (pg/ml), mean (SD) 29.6 (44.1) 19.2 (28.8) 0.07
Leukocytes (per μl), mean (SD) 10,004,4 (11,096.3) 7706.1 (2334) 0.04
Lymphocytes (per μL), mean (SD) 2334 (1987.4) 2398.5 (965.7) 0.77
Neutrophils (per μl), mean (SD) 5920 (2469.1) 4464.2 (2136.7) < 0.001
NLR, mean (SD) 3.1 (1.8) 2.1 (1.5) < 0.001
Platelets (per μl), mean (SD) 295,114,1 (124,102.4) 243,402.4 (72,978.9) 0.001
MPV (fl), mean (SD) 8.4 (1.2) 8.9 (1) 0.003
PLR, mean (SD) 154 (86.6) 118.5 (72.1) 0.003
Fibrinogen (mg/dl), mean (SD) 461 (198.7) 392.5 (166.5) 0.07
A1AT (mg/dl), mean (SD) 174 (49.9) 136.8 (29.1) < 0.001
IgE (kU/l), mean (SD) 155,7 (109.7) 177.8 (569.3) 0.78
CRP (mg/l), mean (SD) 22 (31.7) 6.1 (8.8) < 0.001
Cholesterol (mg/dl), mean (SD) 178.3 (37.1) 201.8 (37.1) < 0.001
Bilirrubin (mg/dl), mean (SD) 0.6 (0.3) 0.6 (0.2) 0.50
LC: lung cancer; COPD: chronic obstructive pulmonary disease; BMI: Body mass index; GOLD: Global Initiative for Obstructive Lung Disease; GesEPOC A: non
exacerbators, according to the Spanish Guidelines of COPD; CAT: COPD Assessment Test; FEV1: forced expiratory volume in the first second; DLCO: carbon
monoxide diffusion capacity; IL: interleukin; NLR: neutrophil/lymphocyte ratio; MPV: mean platelet volume; PLR: platelet/lymphocyte ratio; A1AT: alpha 1-
antitripsin; IgE: E immunoglobulin, CRP: C reactive protein
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descriptive boxplots for all inflammatory markers in
the three groups of patients.
We developed a multivariate logistic regression model
comparing cases and controls (Table 3). High neutrophil
and A1AT levels and low cholesterol levels were the
only significant variables in the multivariate analysis.
Therefore, those were the variables chosen for their
stratification in terciles and their inclusion in the score.
It can be observed that three variables are associated sig-
nificantly with the probability of being a case: patients
with LC + COPD had significantly higher levels of neu-
trophils [OR 4.90 (95%CI 1.60–14.94 for those in the
highest tercile of neutrophils, p = 0.005] and A1AT [OR
3.6 (95%CI 1.23–10.53), for those in the highest tercile
of A1AT, p = 0.019] and lower cholesterol levels [OR
2.91 (95%CI 1.08–7.85), for those in the lowest tercile of
cholesterol, p = 0.03] than COPD controls. The point
scoring system shown in Table 4 was used to measure
the magnitude of the association of each of the signifi-
cant factors in the multivariate analysis with the odds of
being a case, thus leading to the development of a risk
score. Performance and ROC curves of this risk score
are presented on Fig. 2 and Table 5. Based on our model
and assuming a prevalence of 25% among COPD pa-
tients, we reached a sensitivity of 80%, with an optimal
negative predictive value (NPV) of 90.7% [7].
We repeated the univariate and multivariate analyses
excluding patients with advanced LC stage, to minimize
the effect of higher inflammation levels in this kind of
tumours. We found that in local LC + COPD, A1AT was
significantly higher than in COPD patients: OR 1.02
(1.00–1.03); p = 0.03, with an AUC of 66.4 (Table 6).
Table 2 Characteristics of patients with LC only
LC patients without COPD
Gender (male), n (%) 63 (71.6)
Age, mean (SD) 65.7 (10.9)
BMI, mean (SD) 29.3 (5.3)
Laboral exposure, n (%) 28 (33.7)
Tobacco history, n (%) 73 (83)
Active smokers, n (%) 39 (44.3)
Pack-years, mean (SD) 40.3 (23.11)
SCLC, n (%) 4 (4.9)
Adenocarcinoma n(%) 42 (54.5)
Squamous, n (%) 20 (25)
Advanced stage at diagnosis, n (%) 41 (48.2)
FEV1 (%), mean (SD) 87 (20.8)
DLCO (%), mean (SD) 82.2 (20.3)
Charlson index, mean (SD) 2 (2.2)
LC: lung cancer; COPD: chronic obstructive pulmonary disease; BMI: Body mass
index; SCLC: small cell lung cancer; FEV1: forced expiratory volume in the first
second; DLCO: carbon monoxide diffusion capacity
Fig. 1 Descriptive comparison between levels of biomarkers in the
three groups of patients
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Discussion
Our results suggest that a panel of 3 biomarkers out of a
panel of 16, which are easy to assess, might be able to
detect LC in patients presenting COPD. As we have pre-
viously stated, evidence suggests that COPD is a risk fac-
tor for developing LC [7], and one of the underlying
mechanisms described is inflammation. Chronic inflam-
mation has long been associated with carcinogenesis,
contributing to 25% of all human cancers [8]. We have
observed that neutrophils, A1AT and cholesterol are as-
sociated with the risk of LC in COPD patients, and if
they are used combined they might predict LC risk with
an AUC close to 80%. If confirmed in other studies,
these results could be relevant since LC is frequent
among COPD patients and their use might detect the
disease in earlier stages predicting a better clinical
outcome.
Evidence suggests that COPD is a risk factor for devel-
oping LC [7], and one of the underlying mechanisms de-
scribed is inflammation. Chronic inflammation has long
been associated with carcinogenesis, contributing to 25%
of all human cancers [8] and systemic inflammation has
also been shown to be a relevant manifestation of COPD
[25].
As exposed in Additional file 1: Table S1, several
markers have shown associations with both COPD and
LC. Leukocytes, TNF-α, IL-6, IL-8, cholesterol, bilirubin
and fibrinogen levels increase mortality in COPD
patients, whereas white blood and platelet markers are
associated with a risk of COPD exacerbations [10, 11,
26–28]. Also, elevated IgE levels can be found in COPD
patients [29]. In addition, TNF-α, IL-6, IL-8, NLR, PLR,
IgE have been associated with LC risk in healthy sub-
jects, being IL-6, lymphocytes, neutrophils, NLR, plate-
lets, PLR, fibrinogen, A1AT, CRP and bilirubin poor
prognostic factors in LC patients [11, 14, 30–32].
Table 3 Multivariate analysis comparing characteristics of cases and controls with variables stratified by terciles
Variable Cases, n (%) Controls, n (%) OR (95%CI) a p OR (95%CI) b p
A1AT (mg/dl)
Low: < 138 27 (24.7) 41 (49.4) 1 (−) 1 (−)
Medium: ≥138 and < 167 32 (29.3) 32 (38.5) 1.49 (0.66–3.39) 0.34 0.96 (0.38–2.45) 0.94
High: ≥167 50 (45.9) 10 (12) 7.33 (2.80–19.24) < 0.001 3.60 (1.23–10.53) 0.019
Cholesterol (mg/dl)
Low: < 168 40 (36.7) 18 (21.7) 2.91 (1.43–5.94) 0.003 2.91 (1.08–7.85) 0.03
Medium: ≥168 and < 200 44 (40.4) 25 (30.1) 3.73 (1.74–8.00) 0.001 3.03 (1.09–8.41) 0.03
High: ≥200 25 (22.9) 40 (48.2) 1 (−) 1 (−)
Neutrophils (per μl)
Low: < 4007 22 (20.2) 45 (54.2) 1(−) 1 (−)
Medium: ≥4007 and < 5955 42 (38.5) 25 (30.1) 3.35 (1.65–6.84) 0.001 2.95 (1.14–7.60) 0.02
High: ≥5955 45 (41.3) 13 (15.7) 7.08 (3.18–15.77) < 0.001 4.90 (1.60–14.94) 0.005
OR: odds-ratio; 95%CI: confidence interval of a 95%; A1AT: alpha 1-antitripsin; a OR adjusted by age and gender; b OR adjusted by age, gender, alpha 1-antitripsin,
cholesterol and neutrophils
Table 4 Point scoring system for predicting the risk of being a
case
Characteristic Points assigned*
High A1AT levels (≥167mg/dl) 4
Low and medium cholesterol levels (< 200mg/dl) 3
Medium neutrophil levels (≥4007 and < 5955 per μl) 3
High neutrophil levels (≥5955 per μl) 5
A1AT: alpha-1 antitripsin
*A total point score for a given patient is obtained by summing all the points
for each applicable characteristic. The points assigned to each predictor
variable were based on coefficients obtained from the logistic-regression
model adjusted for age, sex, alpha 1-antitripsin, cholesterol and neutrophils
exposed in Table 3
Fig. 2 ROC curve of the risk score
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Table 5 Sensitivity, specificity and predictive values of the risk score
AUC (95%CI) Cut-off value S (%) Sp (%) PPV (%) NPV (%)
Risk score* 0.78 (0.71–0.86) > 3.5 points 80 65.1 43.5 90.7
* The points assigned to each predictor variable were based on coefficients obtained from the logistic-regression model adjusted for age, sex, alpha 1-antitripsin,
cholesterol and neutrophils; S: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value, AUC: area under the curve; CI:
confidence interval
Table 6 Univariate and multivariate analyses comparing characteristics of cases and controls with local LC
UNIVARIATE ANALYSIS
Cases (localized LC + COPD) Controls (COPD) p
Baseline characteristics
Gender (male), n (%) 31 (83.7) 65 (78.3) 0.330
Age, mean (SD) 65.5 (12.9) 64.6 (9.4) 0.680
BMI, mean (SD) 27.7 (4.3) 27.3 (4.5) 0.510
Laboral exposure, n (%) 15 (40.5) 25 (30.1) 0.390
Tobacco history, n (%) 37 (100) 82 (98.8) 0.690
Active smokers, n (%) 20 (54.1) 45 (54.2) 0.340
Pack-years, mean (SD) 45.9 (24) 47.5 (25) 0.750
GOLD I-II, n (%) 5 (13.5) 66 (79.5) 0.260
GesEPOC A (%) 35 (94.6) 80 (96.4) 0.490
Bodex, mean (SD) 0.9 (1.50) 0.8 (1.2) 0.700
CAT, mean (SD) 8.5 (3) 9.7 (7.6) 0.570
FEV1(%), mean (SD) 71.6 (21.3) 71 (20.2) 0.880
DLCO(%),mean (SD) 72.6 (22) 70.4 (22.6) 0.660
Charlson index, mean (SD) 1.3 (1.9) 0,7 (1) 0.010
Inflammatory markers
TNF-α (pg/ml), mean (SD) 11.6 (21) 9.3 (7.4) 0.530
IL-6 (pg/ml), mean (SD) 6.5 (6.1) 6.2 (12.1) 0.850
IL-8 (pg/ml), mean (SD) 22.1 (46.4) 19.2 (28.8) 0.740
Leukocytes (per μl), mean (SD) 8880.9 (4039.1) 7706.1 (2334) 0.110
Lymphocytes (per μL),mean (SD) 2744.9 (3190.1) 2398.5 (965.7) 0.370
Neutrophils (per μl), mean (SD) 5491.1 (2324.7) 4464.2 (2136.7) 0.020
NLR, mean (SD) 2.9 (1.9) 2.1 (1.5) 0.030
Platelets (per μl), mean (SD) 273,594.6 (132,871.4) 243,402.4 (72,978.9) 0.270
MPV (fl), mean (SD) 8.4 (1.3) 8.9 (1) 0.040
PLR, mean (SD) 135 (76.3) 118.5 (72.1) 0.260
Fibrinogen (mg/dl), mean (SD) 395.3 (185.2) 392.5 (166.5) 0.950
A1AT (mg/dl), mean (SD) 157.9 (42.6) 136.8 (29.1) 0.030
IgE (kU/l), mean (SD) 176.5 (216.5) 177.8 (569.3) 0.990
CRP (mg/l), mean (SD) 14.7 (20.6) 6.1 (8.8) 0.009
Cholesterol (mg/dl), mean (SD) 180.1 (44.6) 201.8 (37.1) 0.010
Bilirrubin (mg/dl), mean (SD) 0.73 (0.50) 0.6 (0.2) 0.060
MULTIVARIATE ANALYSIS
OR 95%CI p
A1AT (mg/dl) 1.02 1.00–1.03 0.03
LC: lung cancer; COPD: chronic obstructive pulmonary disease; BMI: Body mass index; GOLD: Global Initiative for Obstructive Lung Disease; GesEPOC A: non
exacerbators, according to the Spanish Guidelines of COPD; CAT: COPD Assessment Test; FEV1: forced expiratory volume in the first second; DLCO: carbon
monoxide diffusion capacity; IL: interleukin; NLR: neutrophil/lymphocyte ratio; MPV: mean platelet volume; PLR: platelet/lymphocyte ratio; A1AT: alpha 1-
antitripsin; IgE: E immunoglobulin, CRP: C reactive protein
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According to our results (Fig. 1), we found differences in
marker levels in patients with LC + COPD, and even in
LC patients without COPD, such as IL- 6, leukocytes,
PLR, fibrinogen, neutrophils, NLR, platelets, A1AT and
CRP. This may indicate that these markers seem to be
more related to the existence of LC than to COPD itself.
In the multivariate analysis we found that some
markers were statistically associated with LC onset:
higher levels of neutrophils and A1AT and lower choles-
terol levels.
Lymphocytes play a crucial role in the cell-mediated
host immune response to tumors. Infiltration of tumors
by lymphocytes correlates with better prognosis in some
cancers, although disease progression is associated with
high leukocyte and neutrophil count [11]. Neutrophils
support angiogenesis by secreting proangiogenic factors
or proteolytic activation of such factors. Also, they en-
sure the collection of epidermal growth factor (EGFR),
transforming growth factor-β1 (TGF- β1), platelet-de-
rived growth factors that contribute to tumorigenesis.
Neutrophils contain both pro- and anti-tumor subpopu-
lations [11]. Neutrophil counts are known to be an inde-
pendent indicator of poor prognosis in LC patients,
whereas low neutrophil counts are associated with lon-
ger survival [33].
Most of the literature available on the relationship be-
tween A1AT and COPD or LC focuses on the deficit of
this protein [34]. However, its role as an inflammatory
marker when it presents high levels has been less stud-
ied. Possible carcinogenic mechanisms have been sug-
gested from the excess activity of neutrophil elastase
[34], which induces tissue damage at the pulmonary
level due to a protease-antiprotease imbalance. More
studies are needed to establish if there is an association
between the A1AT and LC risk. Nevertheless, there is
evidence that A1AT promotes lung adenocarcinoma me-
tastasis [13].
Although hyperlipidemia is a negative prognostic fac-
tor in patients with stomach and prostate cancers, very
few studies have explored the significance of this in LC.
In one trial, HDL, LDL and total cholesterol levels were
lower in LC patients when compared with healthy con-
trols, although only HDL levels were prognostically sig-
nificant [11]. The observed results of cholesterol levels
in this study has not shown to be related to statin con-
sumption or to the presence of cachexia.
In this study, we provide a risk score for COPD pa-
tients with higher risk of CP, achieving high sensitiv-
ity and NPV. In fact, the area under curve is close to
80%, and therefore only 20% of patients using this
score would be misclassified. Our approach involves
the measurement of A1AT, neutrophils and choles-
terol to generate a classification score for each indi-
vidual to predict LC. Although we did reach high
sensitivity and NPV, specificity and positive predictive
value were modest. This was expected since the alter-
ation of any of the selected markers is not specific
for LC, given that they are markers that show high
heterogeneity among patients, that they can be modi-
fied by the different comorbidities, and that there is
an important variability that it is shown in the size of
some of the confidence intervals [35].
We repeated the analyses in patients with COPD and
localized LC, in order to minimize biases due to higher
inflammation levels in patients with advanced LC, given
that patients with local LC would be the objective in the
case of an eventual LC screening. In this case, the only
parameter which was significantly higher in patients with
LC + COPD was A1AT, although the number of patients
in the group of cases was considerably reduced (37 pa-
tients), which limits the conclusions that can be drawn
from this subgroup of patients. It is therefore pending if
this panel results are maintained when using LC patients
at an early stage presenting COPD.
The use of risk prediction models may inform selec-
tion of subjects most likely to benefit from computed
tomography screening; and risk markers such as A1AT,
neutrophils or cholesterol may provide useful risk infor-
mation in addition to questionnaire information on to-
bacco exposure history. Inflammation markers are
unlikely to provide enough added risk information on
their own, but in combination with other risk markers
they may be useful for risk stratification.
Regarding LC characteristics, the most frequent histo-
logical type was adenocarcinoma, which goes in line with
other studies [5]. SCLC was significantly higher in LC +
COPD patients and there was a trend, although not sig-
nificant for squamous LC in this group of patients. This
study found that smoking had a significantly higher ef-
fect on the SCLC risk of COPD subjects, compared with
non-COPD subjects [36]. Also, COPD status was inde-
pendently associated with SCLC risk when adjusted for
age, gender, and smoking. Squamous LC was also more
frequent in smokers and has been associated with the
presence of emphysema [37].
Our study shows several limitations, inherent to its
case-control design. The number of controls (COPD) is
slightly lower than the number of cases (LC + COPD),
although we have a second control group of patients
with LC without COPD. Furthermore, the score created
should be classified as exploratory, though it has rela-
tively high discrimination power. It has to be validated
against other cohorts of patients from other settings. On
the positive side, study groups are very similar regarding
gender and age distribution. In addition, there are limita-
tions derived from the nature of the markers that, as
previously discussed, are not very specific and may
present a great inter and intraindividual variability.
Mouronte-Roibás et al. Respiratory Research          (2019) 20:198 Page 8 of 10
Our study also presents a series of advantages. This is
the first work analyzing a panel of 16 blood markers in
a subgroup of patients with underlying COPD, with ad-
justments by stage, histological type, emphysema and
smoking. Also, we added a second control group of
patients with LC, to show that some markers are more
related to the existence of LC than to COPD itself.
Most patients presented with a mild COPD. This is
useful, as they represent the group most likely to bene-
fit from more aggressive approaches of a malignancy.
On the other hand, a very complete collection of vari-
ables was made, and the sample size is very acceptable.
The whole Galician population has public health cover-
age, meaning there was no selection bias for our sample
as we recruited more than 95% of all LC cases diag-
nosed in the referral area during the study period. We
must consider that, despite a reasonable but modest
sample size, we have included in the logistic regression
model five variables of which three remained statisti-
cally significant, regardless of sex and age, which is why
they are good predictors of the risk of being a patient
with LC and COPD, which makes our results relevant.
In addition, our risk score comprises only 3 parameters
which may be analyzed routinely. This makes our risk
score simple and affordable, and it may prove useful at
guiding decision-making in clinical practice, such as
whether to implement a LC screening system for at-risk
patients, or even modify the probability of malignancy
scales when evaluating a pulmonary nodule.
Conclusions
Patients with COPD who also suffer from LC have
higher levels of A1AT and neutrophils and lower choles-
terol. These markers seem to be more related to the
presence of LC than to COPD itself, since they are in-
creased in patients with LC without COPD. In patients
with LC + COPD at localized stage, A1AT is significantly
higher. The combination of A1AT, neutrophils and chol-
esterol in the risk score variable presents a high sensitiv-
ity and NPV, so it can be a useful tool when identifying
patients with LC + COPD. However, although sensitive,
these markers are not specific of LC, and more studies
are needed to inform selection of COPD subjects most
likely to benefit from computed tomography screening
or selection of nodules at higher risk of being malignant,
as risk markers such as A1AT, neutrophils and choles-
terol may provide useful risk information in addition to
clinical questionnaires.
Additional file
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